# Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

> **NCT05315700** · PHASE1,PHASE2 · RECRUITING · sponsor: **ORIC Pharmaceuticals** · enrollment: 350 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** ORIC-114
- **DRUG:** Chemotherapy drug

## Key facts

- **NCT ID:** NCT05315700
- **Lead sponsor:** ORIC Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-10
- **Primary completion:** 2026-09
- **Final completion:** 2027-09
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2025-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05315700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05315700, "Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05315700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*